Subscribe To

Price Alert Latest News Economic Calendar News

REGN / US FDA declines to approve Regeneron high-dose Eylea

The U.S. Food and Drug Administration on Tuesday declined to approve a higher-dose version of Regeneron Pharmaceuticals' blockbuster treatment Eylea, the company said, marking a blow in the drugmaker's plans to defend the eye drug against a fast-gaining rival. Read More

Demo Live Account See Partner Details

Content Topics

Declines

Approve

Regeneron

High

Dose

Eylea

High dose

Stock

REGN

Posted: Jun 27 2023, 14:58

Author Name: Reuters

REGN News

By Market Watch
November 2, 2023

Regeneron Pharma's adjusted earnings beat estimates

Regeneron Pharmaceuticals Inc.'s stock REGN, +1.46% rose fractionally on Thursday after the drug maker said its profit dropped by 23%, while its adjus

By Reuters
November 2, 2023

Regeneron beats quarterly profit estimates on eczema treatment strength

Regeneron Pharmaceuticals on Thursday beat Wall Street estimates for third-quarter profit, driven by strong demand for its eczema treatment Dupixent.

By Zacks Investment Research
November 1, 2023

Curious about Regeneron (REGN) Q3 Performance? Explore Wall Street Estimates for Key Metrics

Besides Wall Street's top -and-bottom-line estimates for Regeneron (REGN), review projections for some of its key metrics to gain a deeper understandi

By The Motley Fool
October 16, 2023

2 Healthcare Stocks Near 52-Week Highs Still Worth Buying

Healthcare stocks, on balance, haven't been great investments in 2023. Regeneron Pharmaceuticals and Vertex Pharmaceuticals have been two glaring exce

By Zacks Investment Research
October 6, 2023

Will Regeneron (REGN) Beat Estimates Again in Its Next Earnings Report?

Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely bea

By The Motley Fool
October 5, 2023

This Market-Beating Stock Just Gave Investors More Reasons to Invest

Regeneron recently earned a key regulatory approval. The company also expanded its pipeline with an acquisition.

By GlobeNewsWire
September 28, 2023

Regeneron to Report Third Quarter 2023 Financial and Operating Results and Host Conference Call and Webcast on November 2, 2023

TARRYTOWN, N.Y., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its third quart

By The Motley Fool
September 20, 2023

This Recent FDA Approval Could Give Regeneron's Top Line a Big Boost

Regeneron's sales growth rate has been struggling over the past year. Revenue from its top-selling drug, Eylea, fell 7% in the most recent quarter.

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.